Adalimumab vs active comparators
Adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
6 questions · 6 findings · 1 reviews
No studies found 3 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 33.3%High 1 · 16.7%
Adalimumab vs placebo
Adverse events · Participants with Crohn's disease in remission
Adalimumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
- RR 1.01 [0.94, 1.09]4 studies · 1012 participantsHigh
Adalimumab vs active comparators
Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Adalimumab vs placebo
Serious adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.56 [0.39, 0.8]4 studies · 1012 participantsModerate
Adalimumab vs active comparators
Withdrawals due to adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Adalimumab vs placebo
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.59 [0.38, 0.91]4 studies · 1012 participantsModerate